

Review of: "[Perspective] Exploring the Synergistic Approach of Dual GLP-1 Agonist with Degludec Basal Insulin for Early Type 1 Diabetes Treatment for Albumin-Insulin Producing Cells Expression"

Rakesh Mishra¹

¹ Dr. D.Y. Patil Vidyapeeth, Pune

Potential competing interests: No potential competing interests to declare.

The article entitled "[Perspective] Exploring the Synergistic Approach of Dual GLP-1 Agonist with Degludec Basal Insulin for Type 1 Diabetes Treatment for Albumin-Insulin Producing Cells Expression" offers fascinating insights. This study presents valuable information for advancing type 1 diabetes treatment research. The combined use of Dual GLP-1 Agonist with Degludec Basal Insulin could potentially revolutionize Type 1 Diabetes management and treatment. It is important to note that the study's limitation lies in the small number of participants, which emphasizes the need for further investigation. Additionally, the authors' hypothesis gains support from the intriguing observation that liver cells have the ability to reprogram into insulin-producing cells. This characteristic holds great promise for regenerative medicine approaches and holds significant potential for DM1 treatment. Nevertheless, there is ongoing debate surrounding this issue, although recent evidence suggests that human hepatocytes do not express the GLP-1 receptor. The proposed treatment strategy for recently diagnosed DM1 patients, involving the use of GLP-1 analogues in combination with insulin, receives some theoretical backing; however, certain aspects still require clarification.